MedTrace Logo

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

NCT00489086 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-10-29

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.

Conditions

  • Neoplastic Syndrome

Interventions

DRUG

tazarotene

Tazarotene is a member of the acetylenic class of retinoids.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • UCSF Benioff Children's Hospital Oakland

    lead OTHER

Principal Investigators

  • Ervin Epstein, MD · UCSF Benioff Children's Hospital Oakland

  • David R. Bickers, MD · Herbert Irving Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489086 on ClinicalTrials.gov